ATE456952T1 - Löslich gemachte topoisomerase-gifte - Google Patents

Löslich gemachte topoisomerase-gifte

Info

Publication number
ATE456952T1
ATE456952T1 AT02801198T AT02801198T ATE456952T1 AT E456952 T1 ATE456952 T1 AT E456952T1 AT 02801198 T AT02801198 T AT 02801198T AT 02801198 T AT02801198 T AT 02801198T AT E456952 T1 ATE456952 T1 AT E456952T1
Authority
AT
Austria
Prior art keywords
formula
soluble
compounds
topoisomerase poisons
preparing compounds
Prior art date
Application number
AT02801198T
Other languages
English (en)
Inventor
Edmond Lavoie
Alexander Ruchelman
Leroy Liu
Original Assignee
Univ Rutgers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Rutgers filed Critical Univ Rutgers
Application granted granted Critical
Publication of ATE456952T1 publication Critical patent/ATE456952T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Toys (AREA)
  • Meat, Egg Or Seafood Products (AREA)
  • Confectionery (AREA)
AT02801198T 2001-11-14 2002-11-14 Löslich gemachte topoisomerase-gifte ATE456952T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33273401P 2001-11-14 2001-11-14
PCT/US2002/036901 WO2003041660A2 (en) 2001-11-14 2002-11-14 Solubilized topoisomerase poisons

Publications (1)

Publication Number Publication Date
ATE456952T1 true ATE456952T1 (de) 2010-02-15

Family

ID=23299632

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02801198T ATE456952T1 (de) 2001-11-14 2002-11-14 Löslich gemachte topoisomerase-gifte

Country Status (15)

Country Link
US (4) US7049315B2 (de)
EP (3) EP1465625B1 (de)
JP (3) JP4628675B2 (de)
KR (1) KR20050044491A (de)
AT (1) ATE456952T1 (de)
AU (1) AU2002363658B2 (de)
CA (1) CA2467774C (de)
CY (1) CY1110631T1 (de)
DE (1) DE60235287D1 (de)
DK (1) DK1465625T3 (de)
ES (1) ES2340473T3 (de)
MX (1) MXPA04004606A (de)
PT (1) PT1465625E (de)
SI (1) SI1465625T1 (de)
WO (1) WO2003041660A2 (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60228484D1 (de) 2001-11-14 2008-10-02 Univ Rutgers Cytotoxische mittel
ATE456952T1 (de) 2001-11-14 2010-02-15 Univ Rutgers Löslich gemachte topoisomerase-gifte
DE60225943T2 (de) 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
JP4789414B2 (ja) 2001-11-14 2011-10-12 ラトガーズ，ザ ステイト ユニバーシティ 可溶化トポイソメラーゼ毒性剤
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
WO2004014906A2 (en) * 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003265405A1 (en) * 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted heterocycles as topoisomerase i targeting agents
AU2003290818A1 (en) 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents
CA2573190A1 (en) * 2004-07-09 2006-01-26 Medisyn Technologies, Inc. Mt477 and related compounds for the treatment of various cancers
CN101505599A (zh) * 2006-05-24 2009-08-12 雷迪博士实验室有限公司 5(s)-(2′-羟基乙氧基)-20(s)-喜树碱及其制备和治疗癌症的应用
WO2010044885A2 (en) 2008-10-17 2010-04-22 Whitehead Institute For Biomedical Research Soluble mtor complexes and modulators thereof
TW201038578A (en) * 2009-01-30 2010-11-01 Univ Rutgers Methods to treat cancer
DK2403856T3 (da) 2009-03-06 2013-04-08 Univ Rutgers Methylendioxybenzo[i]phenanthridinderivater anvendt til behandling af cancer
WO2010127360A1 (en) * 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2010127363A1 (en) 2009-05-01 2010-11-04 Rutgers, The State University Of New Jersey Toposiomerase inhibitors
WO2012015875A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating hematological malignancies
WO2012015901A1 (en) * 2010-07-28 2012-02-02 Genzyme Corporation Methods for treating gastric and pancreatic malignancies
WO2013154778A1 (en) 2012-04-11 2013-10-17 Dana-Farber Cancer Institute, Inc. Host targeted inhibitors of dengue virus and other viruses
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
CA3019945A1 (en) 2016-04-04 2017-10-12 Rutgers, The State University Of New Jersey Topoisomerase poisons
CN111925370B (zh) * 2020-09-01 2023-07-21 湖北科苑生物药业有限公司 一种吡嗪并吡唑并萘啶类化合物及其制备方法与应用
JP2024522389A (ja) * 2021-04-29 2024-06-19 ハイスリンク セラピューティクス 抗体薬物複合体の調製方法および使用
CN114335101B (zh) * 2021-12-28 2024-11-22 深圳市华星光电半导体显示技术有限公司 显示面板及其制备方法

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2981731A (en) * 1961-04-25 Acridine derivatives
US2985681A (en) * 1953-08-28 1961-05-23 Knoll Ag Phenylacetic acid and aminoalkyl esters thereof
US2985661A (en) * 1956-02-06 1961-05-23 American Cyanamid Co Preparation of 2(omicron-aminophenyl)-benzimidazole
US2915523A (en) * 1956-12-03 1959-12-01 Parke Davis & Co Benzacridine compounds
US3272707A (en) * 1964-07-17 1966-09-13 Smith Kline French Lab Pharmaceutical compositions and methods for their use
CH420045A (de) * 1964-09-01 1967-03-15 Ciba Geigy Verwendung von neuen Poly-azolen als optische Aufhellmittel für textile organische Materialien
US3267107A (en) * 1964-09-17 1966-08-16 American Home Prod 3-(4'-5'-methylenedioxy-phenyl)-7, 8-dimethoxy-1, 2, 3, 4,-tetrahydroisoquinolines
US3849561A (en) * 1964-10-20 1974-11-19 S Naruto Anti-peptic ulcer substance from corydalis tubers
DE1670684A1 (de) * 1966-04-01 1970-12-03 Hoechst Ag Verfahren zur Herstellung von basisch substituierten Bis-benzimidazol-derivaten
US3542782A (en) * 1967-03-15 1970-11-24 Sandoz Ag 5,6-dihydro-8h-isoquino(1,2-b)quinazolines
JPS4942700A (de) * 1972-08-25 1974-04-22
US3912740A (en) * 1974-02-28 1975-10-14 Us Health Method for the preparation of oxygenated benzo{8 c{9 phenanthridine compounds
PT73763B (fr) 1981-10-01 1983-10-26 Quatrum Empresa Nacional De Qu Procede pour la preparation de nouveaux epoxides d'alkaloides benzofenantridiniques et de compositions pharmaceutiques qui les contiennent
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
US5153178A (en) * 1982-05-14 1992-10-06 Maroko Peter R Compositions and method of treatment for improving circulatory performance
US4749708A (en) * 1982-05-14 1988-06-07 Maroko Peter R Composition for improving circulatory performance
IE55519B1 (en) 1982-05-14 1990-10-10 Maroko Peter R Use of a protoberberine alkaloid and composition containing same
US4980344A (en) * 1982-05-14 1990-12-25 Maroko Peter R Compositions for improving circulatory performance
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
JPS61130289A (ja) * 1984-11-29 1986-06-18 Ss Pharmaceut Co Ltd １３−プロピルベルベリンの塩
FR2595356B1 (fr) * 1986-03-05 1991-05-24 Pasteur Strasbourg Universite Derives des nitro ou aminobenzyltetrahydroisoquinoleines, procedes d'obtention, compositions pharmaceutiques les contenant, proprietes pharmacologiques et applications
US5244903A (en) * 1987-03-31 1993-09-14 Research Triangle Institute Camptothecin analogs as potent inhibitors of topoisomerase I
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
SU1530628A1 (ru) 1987-11-20 1989-12-23 Ленинградский Технологический Институт Им.Ленсовета Тригидрохлорид 2-[2-фенил-5(6)-бензимидазолил]-N-(3-диметиламинопропил)-5(6)-бензимидазолкарбоксамида в качестве флуоресцентного красител дл исследовани ДНК
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5106863A (en) * 1990-03-26 1992-04-21 Ortho Pharmaceutical Corporation Substituted imidazole and pyridine derivatives
US5135934A (en) * 1990-07-06 1992-08-04 Du Pont Merck Pharmaceutical Company 3-phenyl-5,6-dihydrobenz(c) acridine-7-carboxylic acids and related compounds as immunosuppressive agents
US5126351A (en) * 1991-01-24 1992-06-30 Glaxo Inc. Antitumor compounds
DE4116593C1 (de) * 1991-05-22 1993-01-07 Fa. Hermann Heye, 3063 Obernkirchen, De
US5223506A (en) 1991-06-04 1993-06-29 Glaxo Inc. Cyclic antitumor compounds
US5428040A (en) * 1993-08-31 1995-06-27 The Du Pont Merck Pharmaceutical Company Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents
ES2177583T3 (es) 1993-09-28 2002-12-16 Kyowa Hakko Kogyo Kk Nuevo compuesto tetraciclico.
PL324034A1 (en) 1995-05-17 1998-05-11 Univ Rutgers Tribenzimidazoles useful as inhibitors of topoisomerase i
US5807874A (en) * 1995-05-17 1998-09-15 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
US5767142A (en) * 1996-03-20 1998-06-16 Rutgers, The State University Of New Jersey Trisbenzimidazoles useful as topoisomerase I inhibitors
KR19990082488A (ko) 1996-02-12 1999-11-25 루트거스, 더 스테이트 유니버시티 오브 뉴 저지 토포이소머라제 억제제로서의 코르알린 동족체
US5770617A (en) 1996-03-20 1998-06-23 Rutgers, The State University Of New Jersey Terbenzimidazoles useful as antifungal agents
TR199900636T2 (xx) * 1996-09-23 1999-10-21 Rutgers, The State University Of New Jersey Anti-t�m�r ajanlar� olarak ikameli/katk�l� heterosayk�llar.
US6140328A (en) * 1997-12-12 2000-10-31 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
CA2347100C (en) 1998-10-14 2010-12-14 Purdue Research Foundation Novel indenoisoquinolines as antineoplastic agents
US6740650B2 (en) * 1999-10-29 2004-05-25 Rutgers, The State University Of New Jersey Heterocyclic cytotoxic agents
EP1228045A2 (de) * 1999-10-29 2002-08-07 Rutgers, The State University Of New Jersey Heterozyklische cytotoxische wirkstoffe
CN1612723A (zh) 2001-11-13 2005-05-04 宝洁公司 包含由抑制剂稳定化的酶的局部组合物
DE60225943T2 (de) * 2001-11-14 2009-01-29 Rutgers, The State University Topoisomerase-giftmittel
JP4789414B2 (ja) * 2001-11-14 2011-10-12 ラトガーズ，ザ ステイト ユニバーシティ 可溶化トポイソメラーゼ毒性剤
ATE456952T1 (de) * 2001-11-14 2010-02-15 Univ Rutgers Löslich gemachte topoisomerase-gifte
DE60228484D1 (de) * 2001-11-14 2008-10-02 Univ Rutgers Cytotoxische mittel
US7493607B2 (en) * 2002-07-09 2009-02-17 Bluerisc Inc. Statically speculative compilation and execution
WO2004014918A1 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted topoisomerase agents
AU2003265405A1 (en) 2002-08-09 2004-02-25 Edmond J. Lavoie Nitro and amino substituted heterocycles as topoisomerase i targeting agents
WO2004014906A2 (en) 2002-08-09 2004-02-19 Rutgers, The State University Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
AU2003290818A1 (en) * 2002-11-12 2004-06-03 Edmond J. Lavoie Topoisomerase-targeting agents

Also Published As

Publication number Publication date
EP1465625A2 (de) 2004-10-13
JP4628675B2 (ja) 2011-02-09
CA2467774C (en) 2011-09-20
JP2005511617A (ja) 2005-04-28
MXPA04004606A (es) 2004-09-10
US7781587B2 (en) 2010-08-24
CY1110631T1 (el) 2015-04-29
US20060052381A1 (en) 2006-03-09
EP2196205A1 (de) 2010-06-16
US7049315B2 (en) 2006-05-23
DE60235287D1 (de) 2010-03-25
EP1465625A4 (de) 2005-06-08
EP2286812A1 (de) 2011-02-23
JP2013166801A (ja) 2013-08-29
US7517883B2 (en) 2009-04-14
EP1465625B1 (de) 2010-02-03
AU2002363658B2 (en) 2008-09-11
JP5337104B2 (ja) 2013-11-06
SI1465625T1 (sl) 2010-06-30
WO2003041660A2 (en) 2003-05-22
WO2003041660A3 (en) 2003-10-16
US20110136812A1 (en) 2011-06-09
KR20050044491A (ko) 2005-05-12
US8389721B2 (en) 2013-03-05
ES2340473T3 (es) 2010-06-04
PT1465625E (pt) 2010-03-09
US20090239871A1 (en) 2009-09-24
DK1465625T3 (da) 2010-05-31
US20050009824A1 (en) 2005-01-13
CA2467774A1 (en) 2003-05-22
JP2010184942A (ja) 2010-08-26

Similar Documents

Publication Publication Date Title
ATE456952T1 (de) Löslich gemachte topoisomerase-gifte
EP1652847A3 (de) Chinolin- und Chianzolinderivate zur Behandlung von Tumoren
WO2002080846A3 (en) Epothilone derivatives and methods for making and using the same
TR200200717T2 (tr) Terapötik kinazolin türevleri.
BRPI0411365A (pt) derivados de aminopiridina
IL173032A0 (en) Pyridazine derivatives and their use as therapeutic agents
PL367682A1 (en) Dolastatin 10 derivatives
IL173396A0 (en) Piperazine derivatives and their use as therapeutic agents
MY136430A (en) N-adamantylmethyl derivatives, pharmaceutical compositions containing them and processes for their preparation
ATE316083T1 (de) Adamantanderivate
EP1453812A4 (de) Cytotoxische mittel
ATE390923T1 (de) Topoisomerase-giftmittel
EE200000472A (et) Kasvajavastased toimeained
ATE424200T1 (de) Solubilisierte topoisomerase-gift-mittel
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
WO2004014906A3 (en) Nitro and amino substituted dibenzonaphthyridines as topoisomerase agents
EA200501233A1 (ru) 4-аминопиримидин-5-он
WO2004044174A3 (en) Topoisomerase-targeting agents
BR0309996A (pt) Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias
SE0202693D0 (sv) Compounds
SE0202692D0 (sv) Compounds
TW200510370A (en) Urea derivatives
WO2005016958A3 (en) Compounds for treating tumors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1465625

Country of ref document: EP